In order to survey the quality of the marketed cardiotonics preparations in Taiwan area, a total of 27 samples of amlodipine besylate cardiac vessel drug preparations were acquired from different counties and cities in Taiwan from January to September 2010. Samples were analyzed by the methods as described in the USP 34 with authorized specifications. The items of analysis included the appearance, average weight, identifcation, assay, dissolution, content uniformity, and percentage of organic impurity. The results showed that two samples (7.4%) failed to meet the specification of organic impurity. Others met the compendia requirements for amlodipine besylate. |